This morning Abbott (NYSE: ABT) per a press release stated;
“Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan has granted national reimbursement for the FreeStyle® Libre glucose monitoring system effective September 1, 2017. The revolutionary system will be widely available to the more than 1 million Japanese people ages six and above with diabetes, both Type 1 and Type 2, on insulin therapy. “
This announcement just reinforced our concern on why the FDA is taking so long to approve the Libre. What is it they see or perhaps don’t see that . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.